|
| 舒巴坦-度洛巴坦和依拉环素在耐碳青霉烯类鲍曼不动杆菌中的药物敏感性分析 |
| Susceptibility analysis of sulbactam-durlobactam and eravacycline against carbapenem-resistant acinetobacter baumannii |
| 投稿时间：2025-06-21 |
| DOI：10.3969/j.issn.1000-0399.2026.01.002 |
| 中文关键词: 舒巴坦-度洛巴坦 依拉环素 耐碳青霉烯类鲍曼不动杆菌 药物敏感性 |
| 英文关键词: Sulbactam-durlobactam Eravacycline Carbapenem-resistant Acinetobacter baumannii Antimicrobial susceptibility |
| 基金项目:安徽省教育厅高校科研项目(编号:2023AH053403); 安徽省临床医学研究转化专项(编号:202427b10020042) |
|
| 摘要点击次数: 605 |
| 全文下载次数: 120 |
| 中文摘要: |
| 目的 研究舒巴坦-度洛巴坦（SUD）和依拉环素（ERV）对临床分离的耐碳青霉烯类鲍曼不动杆菌（CRAB）的体外抗菌活性，为临床治疗CRAB提供参考。方法 收集2025年1～6月中国科学技术大学附属第一医院（安徽省立医院）临床分离的非重复CRAB 120株，使用VITEK MS微生物质谱仪和VITEK2 Compact微生物药敏分析仪对分离的菌株进行鉴定和药敏试验。纸片扩散法测定CRAB对SUD和ERV的药物敏感性。采用全基因组测序技术分析CRAB对SUD的耐药机制。结果 CRAB对β-内酰胺类药物、环丙沙星、左旋氧氟沙星、妥布霉素、复方磺胺甲恶唑和多西环素耐药率较高，对米诺环素、替加环素和多粘菌素的耐药率较低。CRAB对SUD和ERV的敏感性较好，120株CRAB仅有5株对SUD耐药，耐药率为4.2%，所有CRAB均对ERV敏感。测序结果显示对SUD耐药的5株CRAB，有2株菌产生金属酶NDM-1，另外3株菌存在PBP3位点突变。结论 SUD和ERV对CRAB均表现出良好的体外抗菌活性，为CRAB感染治疗提供了新的用药选择，临床可以根据药敏结果合理选用。 |
| 英文摘要: |
| Objective To investigate the in vitro antibacterial activity of sulbactam-durlobactam(SUD) and eravacycline(ERV) against clinical isolates of carbapenem-resistant Acinetobacter baumannii(CRAB) and to provide the laboratory evidence for the treatment of CRAB infections. Methods A total of 120 non-duplicate CRAB isolates were collected from the First Affiliated Hospital of University of Science and Technology of China from January to June 2025. Bacterial identification and antimicrobial susceptibility testing were performed using the VITEK MS MALDI-TOF and the VITEK2 Compact. The disk diffusion method was used to determine the susceptibility of CRAB to SUD and ERV. Whole-genome sequencing was employed to analyze the resistance mechanisms of CRAB against SUD. Results CRAB exhibited high resistance rates to β-lactams, ciprofloxacin, levofloxacin, tobramycin, trimethoprim-sulfamethoxazole, and doxycycline, whereas lower resistance rates were observed for minocycline, tigecycline, and polymyxins. Both SUD and ERV demonstrated favorable activity against CRAB. Among the 120 CRAB isolates, only 5 were resistant to SUD(resistance rate: 4.2%), whereas all strains remained susceptible to ERV. Genomic sequencing revealed that among the 5 SUD-resistant CRAB strains, 2 strains produced the metallo-β-lactamase NDM-1, and the other 3 strains had mutations at the PBP3 site. Conclusion Both SUD and ERV demonstrate good in vitro antibacterial activity against CRAB, providing new therapeutic options for the treatment of CRAB infections. Clinical treatment can be guided by the results of antimicrobial susceptibility testing. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
